Profile
Joan Sellers was the founder of Vasculogic LLC, which was founded in 1999, where she held the title of Chief Executive Officer in 2006.
She was a Development Director at Targeted Cell Therapies LLC from 2008 to 2010, and a Scientist at Transkaryotic Therapies, Inc. from 1990 to 1994.
She was also the Chief Technology Officer at Boston Therapeutics, Inc. Dr. Sellers earned a doctorate degree from the State University of New York at Albany in 1985.
Former positions of Joan Sellers
| Companies | Position | End |
|---|---|---|
| Targeted Cell Therapies LLC | Corporate Officer/Principal | 2009-12-31 |
| Vasculogic LLC | Founder | 2005-12-31 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Corporate Officer/Principal | 1993-12-31 |
| NANOMIX CORPORATION | Chief Tech/Sci/R&D Officer | - |
Training of Joan Sellers
| State University of New York at Albany | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
| Targeted Cell Therapies LLC | |
| Vasculogic LLC | |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
- Stock Market
- Insiders
- Joan Sellers
